Next Science knee study publication announcement

Next Science Limited (ASX: $NXS) has announced the publication of a pilot study demonstrating the potential anti-inflammatory benefit of XPERIENCETM in mitigating inflammation following a Total Knee Arthroplasty (TKA). The study findings, which have undergone a peer review process, have been published in the Journal of Orthopaedic Experience & Innovation.

Executive commentary on knee study publication

Next Science's CEO and Managing Director I.V. Hall stated, 'This pilot study by leading orthopaedic surgeon Dr. Andrew Wickline shows that the use of XPERIENCETM has the potential to improve patient outcomes by reducing both infection and inflammation when used in Total Knee Arthroplasty procedures. The results, which first appeared in August 2023 on VuMedi, have now been through a peer review process and published in the Journal of Orthopaedic Experience & Innovation. This publication means the study will now receive broader recognition in the Orthopaedic community. We will continue to work closely with surgeons to conduct clinical research that further investigates the effectiveness of Next Science's products.'

Summary of Next Science knee study publication

Next Science (ASX: $NXS) has published a pilot study demonstrating the potential anti-inflammatory benefit of XPERIENCETM in mitigating inflammation following a Total Knee Arthroplasty (TKA). The study findings, now published in the Journal of Orthopaedic Experience & Innovation, suggest an expanded application for XPERIENCETM in addition to reducing biofilm-based infection rates. Next Science's CEO and Managing Director, I.V. Hall, highlighted the potential to improve patient outcomes by reducing both infection and inflammation when using XPERIENCETM in TKA procedures. The company aims to continue working closely with surgeons to conduct further clinical research to investigate the effectiveness of its products.